Lophora is a drug-development start-up developing new rapid-acting drugs for central nervous system diseases including treatment-resistant depression.
Founded in 2018 Lophora has successfully finished initial characterization of its lead-candidate through funding granted by the BioInovation institute (Novo Nordisk Foundation) and plan to begin first-in-human trials by 2023.
The company has identified and patented a new class of proprietary ligands that share a pharmacological profile with psilocybin, which has shown promising clinical results in the treatment of depression.
Lophora is currently focusing on Treatment-Resistant Depression, but clinical data suggests that the new drug class will be applicable to the treatment of other CNS disorders including anxiety, PTSD and substance abuse.
Lophora holds a unique position in the market for anti-depressant therapies of the future. The company has qualified lead-candidate LPH-5 through pre-clinical operations, expecting IND status by the end of Q1 2023.
Given our unique technology and knowledge of the field, we are confident that we are moving ahead of a global market shift towards Psychedelic-assisted therapy as a treatment for CNS disorders.
Why a novel treatment paradigm?
Get In Touch
Lophora is located at the BioInnovation Institute at COBIS Science Park in Copenhagen, Denmark.
Contact: firstname.lastname@example.org /+45 51 86 84 82